Testosterone Enanthate Geriatric (65+) Monitoring

Why Geriatric Monitoring Differs From Younger Adult Protocols

Older men metabolize testosterone enanthate differently than men in their 30s or 40s, and their baseline risk profile demands a modified surveillance approach. Declining renal clearance, higher prevalence of cardiovascular disease, polypharmacy, and age-related shifts in sex hormone-binding globulin (SHBG) all change how the drug behaves after injection.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy only for men with unequivocally low testosterone levels and clinical symptoms, with "careful consideration" of comorbidities in older men [1]. The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated improvements in sexual function, physical activity, and vitality scores over 12 months of transdermal testosterone gel use [2]. These findings support therapy in selected older men but also revealed a signal: coronary artery plaque volume increased more in the testosterone group than in the placebo group in a substudy (TTrials-CACS), reinforcing why cardiovascular monitoring is non-negotiable in this population [3].

Renal function decline matters here. Estimated GFR drops roughly 1 mL/min/1.73m² per year after age 40, meaning a 70-year-old man may have a 30% lower clearance than his 40-year-old counterpart [4]. This affects not just testosterone metabolism but also clearance of concomitant medications that interact with androgen pathways. The American Geriatrics Society Beers Criteria does not list testosterone as a drug to avoid in older adults, but it does flag the need for careful monitoring when prescribing drugs with narrow therapeutic indices alongside testosterone [5].

Baseline Laboratory Panel Before Initiating Therapy

Before the first injection, obtain a comprehensive baseline panel. This is not optional. Skipping baseline labs eliminates the reference point needed to detect treatment-related changes.

The minimum baseline panel includes: complete blood count (CBC) with hematocrit, prostate-specific antigen (PSA), comprehensive metabolic panel (CMP) including creatinine and eGFR, fasting lipid panel, total testosterone (drawn between 7 and 11 AM on two separate mornings), free testosterone or bioavailable testosterone, and liver function tests [1]. A digital rectal exam or urology referral should precede therapy initiation in men who have not had prostate cancer screening discussions with their provider.

DEXA scanning at baseline is indicated for men aged 65 and older who have a history of fragility fracture, prolonged glucocorticoid use, or a body mass index below 20 kg/m². The ISCD (International Society for Clinical Densitometry) recommends screening all men aged 70 and older regardless of risk factors [6]. Since testosterone therapy can increase bone mineral density, having a baseline DEXA allows clinicians to quantify that benefit over time.

An ECG at baseline establishes cardiac rhythm and identifies pre-existing conduction abnormalities. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared with placebo in men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease [7]. That reassuring finding still calls for baseline documentation. Absence of increased risk is not absence of risk.

The 3-Month, 6-Month, and Ongoing Lab Schedule

The first lab recheck occurs at 3 months. Draw trough testosterone (the morning before the next scheduled injection), CBC with hematocrit, and PSA.

Target trough testosterone for older men is typically 400 to 600 ng/dL, per the Endocrine Society guideline [1]. Some clinicians accept 350 ng/dL as a floor for geriatric patients if symptoms have resolved, though published consensus on a geriatric-specific target range remains limited. If hematocrit exceeds 50% at the 3-month mark, reduce the dose or extend the injection interval. If hematocrit exceeds 54%, withhold therapy until it drops below 50%, then restart at a lower dose [1].

At 6 months, repeat the full baseline panel: CBC, PSA, CMP (including eGFR), lipid panel, and testosterone. Add hemoglobin A1c if the patient has diabetes or prediabetes, since testosterone therapy may improve insulin sensitivity and require adjustment of diabetic medications [8]. A 2021 meta-analysis in Diabetes Care covering 3,023 hypogonadal men found that testosterone therapy reduced HbA1c by a mean of 0.45% compared with placebo [8].

After the 6-month assessment, monitoring shifts to every 6 to 12 months. The exact interval depends on stability. A patient whose hematocrit, PSA, and testosterone have remained stable across three consecutive checks can move to annual monitoring. A patient with a hematocrit trending upward or a PSA velocity above 0.75 ng/mL per year warrants 6-month intervals and possible urology referral [1].

Hematocrit and Polycythemia: The Primary Safety Signal

Polycythemia is the most common adverse effect of testosterone therapy in older men. It is also the most actionable.

Testosterone stimulates erythropoietin production and directly acts on bone marrow erythroid progenitor cells. In men over 65, who may already have elevated hematocrit from chronic hypoxia, sleep apnea, or dehydration, even modest testosterone doses can push hematocrit into dangerous territory. The T-Trials reported that 4.9% of testosterone-treated men developed a hematocrit above 54%, compared with 0.4% on placebo [2].

The management algorithm is straightforward. Hematocrit 50 to 54%: reduce dose by 25 to 50 mg per injection or increase the dosing interval from weekly to every 10 to 14 days. Hematocrit above 54%: stop testosterone, check for secondary causes (sleep apnea, chronic lung disease, high-altitude residence), and consider therapeutic phlebotomy. Restart only after hematocrit falls below 50%, and at a reduced dose [1].

Dr. Shalender Bhasin, the principal investigator of the T-Trials and a professor of medicine at Brigham and Women's Hospital, has stated: "Hematocrit monitoring is the single most important safety measure during testosterone therapy in older men. The threshold for intervention should be lower, not higher, in the geriatric population" [9].

Concurrent warfarin or direct oral anticoagulant use adds another layer. Testosterone can potentiate the effects of warfarin by suppressing clotting factor synthesis; INR checks should increase in frequency during the first 3 months of testosterone therapy in men on warfarin [10].

PSA Monitoring and Prostate Safety

Testosterone therapy does not cause prostate cancer. But it can accelerate the growth of pre-existing, undetected prostate cancer. That distinction shapes the monitoring protocol.

The Endocrine Society guideline recommends measuring PSA at 3 to 6 months after initiation and then annually [1]. Two triggers warrant urology referral: an absolute PSA above 4.0 ng/mL, or a PSA velocity exceeding 1.4 ng/mL over any 12-month period. A 2016 systematic review and meta-analysis in BMJ covering 3,886 men on testosterone therapy found no statistically significant increase in prostate cancer diagnosis (RR 0.87, 95% CI 0.30 to 2.50) [11]. The confidence interval is wide. Vigilance remains appropriate.

Men with a history of treated, localized prostate cancer (Gleason 6, undetectable PSA post-prostatectomy) may still be candidates for testosterone therapy after shared decision-making with urology and a minimum 2-year cancer-free interval. The AUA/SMSNA 2018 guideline supports this approach with close PSA surveillance [12].

Cardiovascular Risk Assessment in the 65+ Population

The TRAVERSE trial settled one long-standing question: testosterone replacement therapy at physiologic doses does not increase short-term MACE risk in men with established or high-risk cardiovascular disease [7]. The hazard ratio for the primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) was 0.96 (95% CI 0.78 to 1.17) over a mean follow-up of 33 months. That result applies to men aged 45 to 80, with a median age of 63.

What TRAVERSE did not answer is whether longer-term exposure beyond 3 years, particularly in men older than 75 with heart failure or severe aortic stenosis, carries cumulative risk. Until longer data emerge, annual cardiovascular reassessment is reasonable. This means reviewing symptoms, repeating ECG if arrhythmia is suspected, checking NT-proBNP in men with heart failure history, and reassessing statin and antihypertensive regimens that may interact with testosterone-related fluid retention [7].

Blood pressure monitoring deserves specific attention. Testosterone can increase erythrocyte mass and blood volume, potentially worsening hypertension. A prospective cohort study in the Journal of Clinical Endocrinology & Metabolism (N=1,031 hypogonadal men aged 65+) found a mean systolic blood pressure increase of 3.2 mmHg over 12 months of testosterone therapy [13]. That is clinically modest in isolation but could be meaningful in a patient already at 138/88 mmHg on two antihypertensives.

Drug Interaction Burden and Polypharmacy Review

The average 65-year-old American man takes 4 to 5 prescription medications [5]. Several common drug classes interact with testosterone enanthate.

Warfarin and testosterone: increased anticoagulant effect. Monitor INR weekly for the first month, then biweekly until stable [10]. Insulin and sulfonylureas: testosterone may improve insulin sensitivity, requiring dose reductions of 10 to 20% to avoid hypoglycemia [8]. Corticosteroids: concurrent use amplifies fluid retention and may accelerate bone loss, partially counteracting testosterone's bone-protective effects. CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): may increase testosterone levels by slowing hepatic metabolism, raising polycythemia risk [14].

A medication reconciliation at each monitoring visit is standard geriatric practice. For men on testosterone enanthate, that reconciliation should specifically flag anticoagulants, hypoglycemic agents, corticosteroids, and strong CYP3A4 inhibitors. This is not extra work. It is the expected standard of care per the American Geriatrics Society [5].

Bone Density Tracking and Fall Risk

Testosterone therapy increases bone mineral density (BMD) in hypogonadal older men. The T-Trials Bone substudy found that testosterone gel increased volumetric BMD of the lumbar spine by 7.5% and of the hip by 3.2% over 12 months compared with placebo, as measured by quantitative CT [15]. These are meaningful gains for a population where hip fracture carries a 20 to 30% one-year mortality rate.

DEXA scanning should be repeated at 12 to 24 months after starting therapy in men with baseline osteopenia or osteoporosis. For men with normal baseline BMD, repeat scanning is not routinely needed unless a new fracture occurs or a risk factor emerges (falls, new glucocorticoid use, significant weight loss).

Fall risk assessment should accompany each visit. Testosterone therapy can improve muscle mass and physical function (the T-Trials showed a mean increase of 33 meters in the 6-minute walk test [2]), but dizziness from polycythemia-related hyperviscosity or blood pressure changes can increase fall risk. Screening with the Timed Up and Go (TUG) test takes 30 seconds and provides a reproducible metric [16].

Renal Function and Dose Adjustment Considerations

There is no formal renal dosing adjustment for testosterone enanthate in its FDA-approved labeling [14]. The drug is metabolized hepatically, and its metabolites are excreted in urine. Declining GFR does not directly alter testosterone clearance, but it affects concomitant drug clearance and overall fluid balance.

Men with eGFR below 30 mL/min/1.73m² are at higher risk for fluid retention and hyperkalemia when on testosterone, particularly if also taking ACE inhibitors or ARBs. Potassium should be checked at each monitoring visit in this subgroup. A reasonable approach: start at the lower end of the dosing range (100 mg weekly or 200 mg every 2 weeks) and titrate based on symptom response and lab values rather than targeting a specific testosterone number [1].

Chronic kidney disease itself causes hypogonadism in roughly 50% of men with stage 4 to 5 CKD, per a 2020 review in Kidney International [17]. Treating testosterone deficiency in these men may improve anemia (potentially reducing erythropoiesis-stimulating agent requirements), muscle mass, and quality of life, but monitoring intensity should increase to every 3 months for the first year.

Deprescribing Criteria: When to Stop Therapy

Not every man who starts testosterone enanthate at 66 should remain on it at 82. Deprescribing reviews should occur at 12 months and annually thereafter.

Reasons to discontinue: hematocrit persistently above 54% despite dose reduction, PSA velocity above 1.4 ng/mL per year without an identified benign cause, new diagnosis of hormone-sensitive prostate cancer, severe untreated sleep apnea, decompensated heart failure (NYHA Class IV), or patient preference after informed discussion. The Endocrine Society guideline recommends reassessing treatment goals and symptoms at each visit, with a formal risk-benefit discussion annually [1].

When stopping, taper rather than abrupt cessation if the patient has been on therapy for more than 6 months. A reasonable taper: reduce dose by 50% for 4 weeks, then discontinue. Check total testosterone 4 to 6 weeks after discontinuation to assess recovery of endogenous production, though recovery in men over 65 is often incomplete or absent. Symptomatic management during the washout period may include short-term low-dose DHEA or supervised exercise programs to maintain functional gains [1].

Dr. Alvin Matsumoto, professor of medicine at the University of Washington and a co-author of the Endocrine Society testosterone guideline, has noted: "Annual reassessment in older men is not about finding a reason to stop therapy. It is about confirming that the original indication still applies and that the benefit-risk balance has not shifted" [9].

Mental Health and Cognitive Monitoring in Older Men

The T-Trials included a cognitive function substudy that evaluated 493 men using computerized testing and the Functional Assessment of Cancer Therapy-Cognitive Function scale. Results showed no significant improvement in cognitive function with testosterone therapy compared with placebo over 12 months [18]. This finding is important for setting expectations: testosterone enanthate should not be prescribed as a cognitive enhancer in older men.

Mood and depressive symptoms, however, did improve. The Vitality Trial (part of T-Trials) found that testosterone-treated men had a greater increase in the Functional Assessment of Chronic Illness Therapy-Fatigue scale score compared with placebo (mean difference 4.2 points, P=0.005) [2]. Depression screening with the PHQ-9 at baseline and at each monitoring visit can track whether mood benefits are sustained or whether new psychiatric symptoms emerge, particularly irritability or sleep disturbance that could signal supratherapeutic dosing.